Abstract
Cisplatin/5-fluorouracil (CF) versus carboplatin/paclitaxel (CT) chemoradiotherapy (CRT) for locoregionally advanced esophageal cancer (LAEC)
Journal of clinical oncology, Vol.35(4_suppl), pp.140-140
02/01/2017
DOI: 10.1200/JCO.2017.35.4_suppl.140
Abstract
140
Background: Disease control and survival outcomes for LAEC are poor despite multimodality treatment with CRT with or without esophagectomy. Without comparative trial data, oncologists select a chemotherapy regimen based on clinical experience and toxicity profile. The present investigation compares LAEC progression free survival (PFS) and overall survival (OS) for CF versus CT. Methods: A retrospective analysis was performed for patients with LAEC from 2003-2012, treated with curative-intent neoadjuvant or definitive concurrent CRT with either CF or CT. Chi-squared tests, Fisher’s exact tests, and t-tests were used to identify significant differences between treatment groups. The Kaplan-Meier method was used to estimate PFS and OS. Results: Of 149 patients with non-metastatic LAEC, 82 met inclusion criteria (n=38 CF, n=44 CT), with 63, 2, and 2 excluded for non-CF/CT CRT, missing data, and <1 month follow-up, respectively. Treatment groups were well balanced, excepting fewer females, lower prior cancer rate, and longer follow-up for the CF group (Table 1). At a median follow-up of 22.7 months (range, 1.8-132.1, median follow-up 58.6 for survivors), 48 patients experienced recurrence (22 CF, 26 CT), and 63 patients died (29 CF, 34 CT). No differences in PFS or OS were demonstrated between treatment groups (Table 1). Conclusions: The present study failed to detect a disease control or survival difference between CF and CT as a component of CRT in neoadjuvant or definitive settings for LAEC. Until randomized trial data are available, oncologists may elect CF or CT based on clinical situations and anticipated sequelae. [Table: see text]
Details
- Title: Subtitle
- Cisplatin/5-fluorouracil (CF) versus carboplatin/paclitaxel (CT) chemoradiotherapy (CRT) for locoregionally advanced esophageal cancer (LAEC)
- Creators
- Michael Marquardt - Univ of Iowa Hosp & Clinics, Iowa City, IACarryn M. Anderson - University of IowaSarah L Mott - University of IowaMuhammad Furqan - University of IowaGerald H. Clamon - University of IowaKalpaj Parekh - University of IowaBryan G. Allen - University of IowaJohn Michael Buatti - University of IowaJohn Morgan Watkins - University of Iowa Hospital and Clinics, Department of Radiation Oncology, Iowa City, IA
- Resource Type
- Abstract
- Publication Details
- Journal of clinical oncology, Vol.35(4_suppl), pp.140-140
- DOI
- 10.1200/JCO.2017.35.4_suppl.140
- ISSN
- 0732-183X
- eISSN
- 1527-7755
- Language
- English
- Date published
- 02/01/2017
- Academic Unit
- Neurosurgery; Cardiothoracic Surgery; Hematology, Oncology, and Blood & Marrow Transplantation; Internal Medicine; Anatomy and Cell Biology; Otolaryngology; Radiation Oncology
- Record Identifier
- 9984288752102771
Metrics
7 Record Views